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Abstract
The phosphoinositide-3 kinase (PI3K) pathway regulates diverse cellular activities related to cell growth, migration, survival,
and vesicular trafficking. It is known that Ebola virus requires endocytosis to establish an infection. However, the cellular
signals that mediate this uptake were unknown for Ebola virus as well as many other viruses. Here, the involvement of PI3K
in Ebola virus entry was studied. A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of
Zaire Ebola virus (ZEBOV). Inhibitors of PI3K and Akt significantly reduced infection by ZEBOV at an early step during the
replication cycle. Furthermore, phosphorylation of Akt-1 was induced shortly after exposure of cells to radiation-inactivated
ZEBOV, indicating that the virus actively induces the PI3K pathway and that replication was not required for this induction.
Subsequent use of pseudotyped Ebola virus and/or Ebola virus-like particles, in a novel virus entry assay, provided evidence
that activity of PI3K/Akt is required at the virus entry step. Class 1A PI3Ks appear to play a predominant role in regulating
ZEBOV entry, and Rac1 is a key downstream effector in this regulatory cascade. Confocal imaging of fluorescently labeled
ZEBOV indicated that inhibition of PI3K, Akt, or Rac1 disrupted normal uptake of virus particles into cells and resulted in
aberrant accumulation of virus into a cytosolic compartment that was non-permissive for membrane fusion. We conclude
that PI3K-mediated signaling plays an important role in regulating vesicular trafficking of ZEBOV necessary for cell entry.
Disruption of this signaling leads to inappropriate trafficking within the cell and a block in steps leading to membrane
fusion. These findings extend our current understanding of Ebola virus entry mechanism and may help in devising useful
new strategies for treatment of Ebola virus infection.
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Introduction
Ebola virus, a member of the family Filoviridae, is an emerging
infectious agent that causes severe and often fatal hemorrhagic
fever in humans and nonhuman primates. In many outbreaks,
especially those caused by Zaire Ebola virus (ZEBOV), mortality
rates close to 90% have been reported [1]. Currently, no vaccine
or therapy is available for Ebola virus hemorrhagic fever.
Significant mortality rate, high transmissibility and lack of
therapeutic and preventive measures make Ebola virus a
potentially serious public health threat.
Ebola viruses are filamentous enveloped viruses. The envelope
contains two virally-encoded glycoproteins, GP1 and GP2, which
together serve as the primary viral determinant for entry into host
cells. The two glycoproteins are produced from a precursor
protein (GP), which is cleaved by a furin-like endoprotease to
generate surface-bound protein GP1 and the transmembrane
protein GP2, the two proteins, remain associated by a disulfide
bridge after cleavage [2]. As with many enveloped viruses, entry of
ZEBOV into cells likely involves virus particles binding to host cell
receptor(s), followed by endocytosis and trafficking through
vesicular compartments, and finally fusion of the virus membrane
to that of the endocytic vesicle. This results in release of the viral
nucleocapsid into the cytoplasm where the subsequent steps of the
replication cycle take place [3]. GP1 is believed to mediate
interaction with the host cell receptor, while GP2 is involved in
membrane fusion [3]. Membrane fusion is believed to involve a
GP2 structural rearrangement triggered by low pH in an
endocytic compartment. In addition, intracellular processing of
GP1 by endosomal cathepsins is also a prerequisite to membrane
fusion [4]. Thus, an important aspect of ZEBOV entry involves
endocytic trafficking into the cell.
Recent work has shown that many viruses exploit host cell
molecules and signaling pathways to facilitate various steps of the
entry process. A critical role of focal adhesion kinase and protein
kinase C was described for endocytosis and endosomal sorting of
West Nile virus in mosquito cells [5], and recently, Rho A and its
upstream tyrosine kinases were implicated in endocytosis and
trafficking of poliovirus [6]. However, for most viruses, especially
enveloped viruses, information on the requirements of cell
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regarding the entry of Ebola virus and the role of the envelope
glycoproteins in cell attachment and endocytosis (reviewed in [7]).
However, our understanding of the role of cell signaling in virus
entry remains limited.
The phosphoinositide-3 kinase (PI3K) pathway is an important
cell signaling pathway that regulates diverse cellular activities
including proliferation, differentiation, apoptosis, migration, metab-
olism, and vesicular trafficking [8]. PI3Ks (OMIM#601232; Online
Mendelian Inheritance in Man database: http://www.ncbi.nlm.nih.
gov/sites/entrez?db=omim) are a family of lipid kinases that are
divided into three classes according to their structure and substrate
specificity. Of these, class I PI3Ks are the most widely studied. They
signal through cell surface protein tyrosine kinase (PTK) or G-
protein coupled (GPC) receptors. Activation of PI3K results in
phosphorylation of phosphatidylinositol-bis phosphates to produce
phosphatidylinositol-triphosphates, which serve as potent second
messengers for downstream signaling. Akt-1 (OMIM#164730), is a
key downstream intermediate in PI3K-dependent signaling. A
variety of molecules are directly or indirectly regulated by Akt,
and serve as downstream effectors to carry out diverse PI3K-
regulated responses [9].
Regulation of vesicular trafficking is one of the oldest recognized
functions of PI3Ks [10]. PI3Ks influence a variety of intracellular
trafficking events that include cargo selection, vesicle formation,
vesicle movement and membrane fusion. This is often through
stimulation of actin turnover [11]. Rac1 (OMIM#602048), along
with other Rho family GTPases, is a key effector in this process
[12]. Therefore the regulation of Rac1 by class 1 PI3Ks, as seen in
many cell types [13–16], provides a mechanism to couple
receptor-ligand interaction to induction of endocytosis as well as
other actin-mediated functions in the cell. Bacterial pathogens
have been shown to take advantage of this mechanism by
stimulating phagocytosis and internalization through PI3K
activation [17,18]. Similarly, interaction of the non-enveloped
adenovirus with receptors on the cell surface was shown to activate
Rac1 and Cdc42 (OMIM#116952) in a PI3K-dependent manner,
and this was required for virus uptake into endosomes [19].
However, similar dependencies for enveloped viruses have not
been described. Here we investigated the role of PI3K cell
signaling pathway in cellular entry of ZEBOV. The findings
indicated that ZEBOV induces activation of PI3K pathway prior
to or during entry and that activity of class 1A PI3Ks is critical for
entry into host cells. Rac1 GTPase was found to be an important
downstream effector in regulating ZEBOV entry. The impact of
inhibiting PI3K, Akt or Rac1 was similar, causing an aberrant
accumulation of ZEBOV particles in intracellular vesicles,
indicating a role of the PI3K-Akt-Rac1 pathway in vesicular
trafficking of virus particles.
Results
PI3K activity is important for an early event(s) in ZEBOV
infection
Several viruses utilize the PI3K-Akt pathway to support
replication in host cells [20–23], however, involvement of this
pathway in early events of infection such as entry has not been
conclusively demonstrated for enveloped viruses. We investigated
the effect of LY294002 (a highly specific inhibitor of PI3K) on
infection by wild type ZEBOV. To determine if the drug was acting
early or late in the infection cycle, cells were exposed to drug only
during the first 2 h of incubation with the virus. Subsequently, the
drug and the unbound virus were removed, and infection was
allowed to continue. As compared to untreated cells, the infection of
ZEBOV was significantly (nearly 10-fold) reduced in cells treated
with LY294002 (p,0.01). In contrast, LY294002 exhibited no
significant effect (p.0.05) on infection by vesicular stomatitis virus
(VSV). A similar level of inhibition of ZEBOV infection was
observed when a specific Akt inhibitor was used (Figure 1). These
data suggested that the PI3K-Akt pathway plays a role in one or
more of the early events in the ZEBOV infection cycle.
ZEBOV interaction with cells directly stimulates activation
of the PI3K pathway
While the above data indicated that the activity of PI3K is
important for early event(s) in ZEBOV replication, it was unclear
if the basal level activity of the PI3K-Akt pathway was sufficient for
infection or if ZEBOV itself was capable of inducing this pathway
to promote infection. To address this question, phosphorylation of
Akt-1 was measured in cells after incubation with ZEBOV. Akt is a
major downstream effector of the PI3K pathway and is
phosphorylated (activated) following activation of PI3K. There-
fore, Akt phosphorylation is often used as an indirect, but reliable
Figure 1. PI3K is important for early step(s) during ZEBOV
infection. Vero-E6 cells were incubated with LY294002 (50 mM) or Akt
inhibitor (10 mM) for 2 h in the presence of virus. Unbound virus and
drug was then removed and cells were cultivated. After 10 d, cells were
fixed in formalin and stained with crystal violet; plaques were then
counted. Effect of the drugs on VSV (Indiana strain) infection was also
tested similarly, except that plaques were counted 2 d after inoculation
of cells. Open bars, ZEBOV; solid bars, VSV (* p,0.01).
doi:10.1371/journal.ppat.1000141.g001
Author Summary
Each year, filoviruses such as Ebola virus claim many
human lives and decimate gorilla populations in Africa.
Infection results in an acute fever often associated with
profuse internal and external bleeding and death rates of
up to 90%. Due to these symptoms and high pathogenic-
ity, these viruses have been heavily publicized in the
media. The first step of infection is entry, where the virus is
taken up and penetrates into the cell, from which it
spreads throughout the body. While it is known that the
cell must engulf the virus by the process of endocytosis,
we know little about how the virus triggers this event.
Here, we use a novel technology to measure penetration
of Ebola virus into the cell in real time and show that Ebola
virus stimulates phosphoinositide-3 kinase, a signaling
molecule known to induce endocytosis. Importantly, drugs
that interfere with this signaling inhibit infection by Ebola
virus and block virus spread. This work provides a
mechanistic insight into how Ebola virus manipulates the
cell to start an infection, may explain part of virus induced
pathogenesis, and provides a potential way to treat this
deadly disease.
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HEK293 cells were incubated with medium containing no serum
(negative control), medium containing 10% fetal bovine serum
(positive control), or c-radiation-inactivated ZEBOV or VSV.
Compared to the negative control, ZEBOV caused a marked (.2-
fold) increase in Akt phosphorylation within 30 min and actually
surpassed the level observed after serum stimulation of cells
(Figure 2). In contrast, VSV had no significant effect on
phosphorylation of Akt-1 over this time interval. These data
suggested that ZEBOV actively and strongly induces the PI3K
pathway very early during the infection process. Since c-radiation-
inactivated virus had been used, it was likely that this stimulation
was the product of direct GP interaction with cell receptors.
The early dependence of ZEBOV infection on PI3K and Akt
activity, and a significant induction of Akt phosphorylation by c-
radiation-inactivated (replication-incompetent) ZEBOV suggested
that the PI3K pathway is likely involved at an early step in
infection, most likely entry.
The PI3K-Akt pathway is critical for entry of ZEBOV
To investigate if the PI3K-Akt pathway played a role in
ZEBOV entry or was required for some other early, but post-entry
step, we adapted a previously described contents mixing assay that
allowed rapid and quantitative measurement of entry of diverse
enveloped viruses up to and including the point of membrane
fusion [24]. The assay, which was originally based on virus
pseudotypes, measures release of a recombinant nef-luciferase
protein, encapsulated within virus particles. The nef peptide serves
to non-specifically target luciferase to cell membranes at the time
of particle budding and so, incorporates luciferase within the
membrane of new virus particles. After cell-virus membrane
fusion, the luciferase becomes accessible to its substrates,
previously loaded into cells, and light is emitted. Here the assay
was adapted for use, first with ZEBOV GP pseudotyped particles
and then with ZEBOV virus-like particles. Both types of virus
particles give a measure of GP function but VLPs, which share a
filamentous structure with native ZEBOV are likely a better model
system for wild type virus. In either case, this is the first time that
this assay technology has been adapted to ZEBOV. Each assay
was applied to determine if the PI3K-Akt pathway played a role in
entry of ZEBOV.
To assess their efficiency in an entry assay, luciferase-containing
pseudotypes with ZEBOV envelope glycoproteins (EVP) or VSV-
G protein (VSVP), and VLPs carrying ZEBOV envelope
glycoproteins (ZEBO-VLP) or VSV-G protein (VSV-VLP) were
produced, sucrose purified and tested on cells. As compared to
particles devoid of envelope glycoproteins, a strong signal was
obtained for each of EVP, VSVP, ZEBO-VLP and VSV-VLP
(Table 1, column 2). The relatively large difference in the signal
between EVP and VSVP correlated to differences in pseudotype
virus titer, as determined by standard infection assays with a GFP
reporter gene (Table 1, column 3) and likely reflects the potency of
the VSV-G relative to ZEBOV GP.
Both EVP and ZEBO-VLPs were then further validated for
specificity of entry into cells. In each case the activity of the
pseudotyped particles reflected that of the VLPs. ZEBOV
neutralizing antibody (KZ52) significantly (,70%) blocked entry
of both EVP and ZEBO-VLP, (Figure 3A) and correlated to that
reported for inhibition of infectious ZEBOV infection at the
concentration of the antibody used here [25] while entry of VSVP
was unaffected. Secondly, ammonium chloride (NH4Cl) and
bafilomycin A1, two well-known inhibitors of endosomal acidifi-
cation, both inhibited the pH-dependent entry of EVP and VSVP,
while they had no effect on entry of a Friend murine leukemia
virus pseudotype (FrVP), a pH-independent virus. Similarly, entry
of ZEBO-VLP was also inhibited by NH4Cl (Figure 3B). Thirdly,
a detailed examination of the entry kinetics of EVPs and ZEBO-
VLPs (Figure 3C) revealed that the peak of the entry signal was
preceded by a pronounced lag and occurred much later than that
for VSV-G bearing particles. This timing was similar to that
reported previously for a pseudotype infection assay [26]. Of note,
both pseudotypes and VLPs entered cells with similar behavior
and timings, indicating that the GP dictated the uptake kinetics
and pathway used by the virus particle, more than the particle
shape. In subsequent studies, the majority of the presented data
are from VLPs but similar outcomes were seen with pseudotyped
particles and are shown for comparison.
To investigate if the PI3K-Akt pathway played a role during the
entry steps of ZEBOV infection, LY294002 and Akt inhibitor
were tested in the entry assay. In each case, cells treated with the
inhibitors exhibited significant reduction in the entry of ZEBOV
GP bearing particles but not for particles bearing VSV-G (Figs. 4A,
B). As a further independent test, a dominant-negative mutant of
the p85 regulatory subunit (OMIM#171833) of class 1A PI3K
(Dp85a) was used to inhibit PI3K-mediated signaling. Dp85a
retains the ability to bind phosphotyrosine residues on upstream
receptors that signal through PI3K but lacks the ability to interact
with the PI3K catalytic domain [27]. Cells were transiently
transfected with either a control plasmid (pcDNA3) or plasmid
expressing Dp85a (pcDNA3:Dp85a) and entry assays performed
using ZEBO-VLPs or VSV-VLPs (Figure 4C). Entry of ZEBO-
VLPs was significantly inhibited in cells expressing Dp85a as
compared to that in cells transfected with the empty vector,
Figure 2. ZEBOV particles induce Akt-1 phosphorylation early
during infection. Serum-starved HEK293 cells were incubated with
serum-free medium (2), medium containing 10% FBS (S), and serum-
free medium containing c-radiation–inactivated ZEBOV (E, MOI=5) or
VSV (V, MOI=5) at 37uC for 30 or 60 min. Subsequently, cells were
washed and lysed, and phosphorylated Akt-1 was detected by Western
blotting (p-Akt-1; top panel). The same membrane was then stripped
and re-probed for total Akt-1 (bottom panel). The bar graph shows a
summary of densitometry analysis of bands, which was performed
using the ImageJ gel analysis package. The ratio of band intensities of
phospho-Akt-1 to total Akt-1 was determined and normalized to the
serum-treated control. Each data point represents mean6SD of 3
experiments.
doi:10.1371/journal.ppat.1000141.g002
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bearing particles was similar in both cell types (Figure 4C).
Dp85a inhibits activity of those PI3K heterodimers that contain
the a-isoform of the p85 regulatory subunit. To test the potential
involvement of other isoforms, entry assays were performed using
pik3R1 (OMIM#171833) knockout (p85a-, p50a-, p55a-defi-
cient) or pik3R2 (OMIM#603157) knockout (p85b-deficient)
mouse embryonic fibroblasts (MEF). Due to lower sensitivity of
the VLP-based assay system in these cells, the experiments were
performed using the pseudotyped virus-based assay. Furthermore,
because of intrinsic resistance of corresponding wild-type MEFs to
infection by VSVP, FrVPs were again used as a control.
Compared to wild-type MEFs, EVP entry was reduced by
.50% in the homozygous knockout cells for pik3R1, while entry
in pik3R2 knockout cells was reduced by 75%. No significant
effect on the entry signal of the FrVP was observed in either cell
type (Figure 4D). These data indicate that both p85a and p85b
containing PI3K heterodimers are involved in entry of ZEBOV.
The above findings strongly indicated that inhibition of PI3K-
Akt pathway blocked ZEBOV infection up to or including the
membrane fusion step. However, this could be due to impaired
virus binding to cells or inhibition at a post-binding step such as
endocytosis, trafficking, or membrane fusion. To further define the
mechanism by which PI3K controls ZEBOV entry, virus binding
to cells was measured. Cells were pretreated with LY294002 or
Akt-1 inhibitor and pseudotyped viruses were bound for 10 min.
Unbound virus was then washed away and cells with residual
bound particles were lysed using non-ionic detergent to release
virus encapsulated luciferase. Compared to DMSO-treated
(control) cells, no significant difference was observed in luciferase
activity in samples that were treated with either LY294002 or Akt-
1 inhibitor, indicating that ZEBOV pseudotype binding to cells
was unaffected (Figure 4E). Similarly, no significant difference was
observed among p85 wild-type, pik3R1
2/2 or pik3R2
2/2MEFs
in their capacity to bind the pseudotyped particles (data not
shown). This suggested that inhibition of the PI3K-Akt pathway
does not influence levels of accessible receptor on the cell surface.
Therefore, the PI3K-Akt pathway most likely plays a role in one or
more post-binding steps involved in entry.
Rac1 serves as a downstream effector of the PI3K-Akt
pathway in ZEBOV entry
Among the possible downstream effectors regulated by PI3K-
Akt pathway, mTOR (OMIM#601231) and Rac1 are most likely
to influence the entry process. mTOR, being a positive regulator
of translation [28], could potentially stimulate synthesis of factors
needed during entry. However, a role of mTOR in ZEBOV entry
was ruled out as rapamycin, a potent inhibitor of mTOR, had no
effect on EVP entry (data not shown).
Rac1, through its regulation of actin polymerization plays a vital
role in various steps involved in endocytosis. In many cell types,
activity of Rac1 is regulated by the PI3K-Akt pathway [13–16].
Therefore, a specific Rac1 inhibitor was tested. A dose dependent
inhibition of ZEBO-VLP was observed peaking at .90%
inhibition at 400 mM without affecting VSV-VLP entry
(Figure 5A). Furthermore, transient expression of a dominant-
negative Rac1 mutant (Rac1-T17N) in cells reduced entry by
.80% (Figure 5B). The extent of ZEBO-VLP entry inhibition
corresponded to the number of cells expressing the dominant-
negative Rac1 (Figure 5C, left panel).
The above findings provided evidence that PI3K-Akt and Rac1
pathways play a role in ZEBOV entry; however, it remained
unclear if the two pathways were linked or acted independently.
To investigate this, cells were made to express a constitutively
active form of Rac1 (Rac1-G12V) in the presence of the Akt
inhibitor. The effects of the inhibitor were significantly reversed
(Figure 5B) by the mutant, indicating, that PI3K-Akt and Rac1 act
sequentially in a pathway that controls entry of ZEBOV, with
PI3K-Akt acting upstream of Rac1. Again, the extent of the effect
of constitutively active Rac1 was proportional to the number of
cells expressing the mutant protein (Figure 5C, middle panel).
Similar data were obtained when EVPs and VSVPs were used in
the assay (data not shown).
Inhibition of PI3K-Akt-Rac1 pathway leads to a blockade
in ZEBOV uptake
Inhibitors of PI3K, Akt and Rac1 had no significant effect on
EVP binding to cells (Figure 4E, and data not shown) indicating
that the action of the PI3K-Akt-Rac1 pathway was likely
important for endocytosis, trafficking and/or membrane fusion
of ZEBOV. To examine this, ZEBOV particles were labeled with
a red fluorescent dye (Alexa Fluor594) and incubated with
HEK293 cells in the absence or presence of LY294002, Akt
inhibitor or Rac1 inhibitor. Cells were also stained for F-actin to
visualize the cell cytoskeleton, and analyzed by confocal
microscopy. In untreated cells, particles were found distributed
evenly throughout the cell cytoplasm. In contrast, after treatment
with each inhibitor, particles accumulated in clusters (Figure 6A).
The drugs were also tested with Vero-E6 cells, a widely used,
ZEBOV permissive cell line. Again, in untreated cells, individual
Table 1. Activity of luciferase-containing pseudotyped virus and virus-like particles in the entry assay.
Luciferase Activity (counts/ml of Virus)
a Virus Titer (cfu/ml)
b
Pseudotype with no envelope protein 0.760.2 1.760.7610
2
EVP 150650 1.260.5610
5
VSVP 3,0006500 2.561.5610
7
VLP with no envelope protein 563N D
ZEBO-VLP 6736171 ND
VSV-VLP 1,272657 ND
ND, not determined; VLPs do not encode an expressed transgene to allow titer determination.
aPseudotyped virus particles or VLPs were pelleted through sucrose and resuspended in 0.01 volumes of the original culture volume. A total of 0.2 ml of virus was used
per assay with 10
6 cells and values were measured after 3 h of incubation.
bVirus was prepared as above and used to infect HEK293-mCAT-1 cells. Titer was determined by limiting dilution using GFP reporter expression to count infected cells.
Values for titer and entry assay are the mean6SD of 3 independent experiments.
doi:10.1371/journal.ppat.1000141.t001
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(Figure 6B). Interestingly, image analysis of serial z-sections
revealed that most of the individual particles were adjacent to
small actin bundles (Figure 6C, left panel, arrow heads) supporting
a requirement for actin involvement in ZEBOV movement
through the cell cytoplasm. Treatment with inhibitors of PI3K,
Akt-1 and Rac1 each gave a similar outcome to that seen in the
HEK293 cells, with clustering of virus particles within a cytosolic
compartment (Figure 6B), possibly of endocytic origin. These
observations suggest that in the absence of PI3K activity, virus
particles are taken into a vesicular compartment, but further
trafficking is blocked.
Discussion
This study describes a novel role for the PI3K cell signaling
pathway in cellular entry of ZEBOV. A number of viruses utilize
the PI3K-Akt cell signaling pathway to promote various steps in
their replication cycle, such as regulation of gene expression and
genome replication. Some bacteria and a few non-enveloped
viruses also utilize this pathway to trigger their invasion and
endocytosis into cells [22,29–32]. This report provides evidence
that the PI3K pathway plays a critical role in cellular entry of
ZEBOV. A previous report suggested that PI3K is involved in
early events in Influenza virus infection [33]. However, a detailed
analysis of the mechanism of action was not performed and a
subsequent study using the same cell type and virus strain failed to
show a requirement of PI3K activity for Influenza virus entry into
cells [34]. Thus, the present report is the first to show involvement
of the PI3K-Akt pathway in entry of an enveloped virus.
The data obtained using the knockout cells provided
information on which subtype of PI3K was important. Inhibition
of pseudotyped ZEBOV entry into pik3R1 knockout (p85a-,
p50a-, p55a-deficient) or pik3R2 knock out (p85b-deficient) cells
suggested that class IA PI3Ks played a prominent role. Entry
inhibition was more pronounced in pik3R2 knockout cells than
in the pik3R1 knockout cells. This was somewhat surprising
given that p85a is a major PI3K regulatory subunit, and deletion
of the pik3R1 gene has a greater phenotypic impact, including
perinatal lethality of homozygous mice accompanied with
extensive hepatocytic and brown fat necrosis, enlarged skeletal
muscle fibers, calcification of cardiac tissue and impaired B-cell
development and proliferation [35,36]. However, a few respons-
es such as T-cell proliferation, and insulin-dependent tyrosine
phosphorylation of insulin receptor substrate-2 were increased in
pik3R2 knockout mice [37,38], indicating that each subtype may
have specialized roles in specific cells and tissues. Indeed, each
binds different sets of proteins [39]. Individual disruption of
pik3R1 or pik3R2 gene was insufficient to confer complete
inhibition of ZEBOV entry and may be due to a partial
redundancy in the function of each or that other PI3K isoforms
may also be involved.
Given the relatively slow entry kinetics of ZEBOV, compared to
VSV, the rapid phosphorylation of Akt by ZEBOV suggests that
induction of the PI3K pathway may be related to a very early
event in the entry process, such as receptor/co-receptor
engagement. The class 1A PI3Ks are mainly activated by
membrane-bound receptor tyrosine kinases (RTKs) [40]. Recent-
ly, Axl, Dtk, and Mer (Tyro3 family RTKs) were shown to serve as
important entry factors for Ebola and Marburg viruses [41]. It was
suggested that these molecules serve to promote endocytosis of
ZEBOV particles; however, the exact mechanism and down-
stream effectors remained unclear. Interestingly, the inhibition of
PI3K or Akt caused virus particles to aberrantly accumulate within
the cell cytoplasm. In many cell types tyro3 family members
trigger PI3K activation, and physical association of PI3K with Axl,
Dtk and Mer has also been demonstrated [42]. ZEBOV
interaction with the tyro3 RTK may then directly or indirectly
trigger activation of PI3K and downstream effectors leading to
virus endocytosis. However, more detailed analyses are required to
further test this model.
Figure 3. Validation of luciferase virus entry assay for ZEBOV
pseudotypes and VLPs. (A) The luciferase entry assay was performed
using EVP (open bars) or VSVP (solid bars) or ZEBO-VLP (diagonally
hatched bars) on HEK293-mCAT-1 cells in the presence of anti-Ebola
virus neutralizing antibody (KZ52, 0.3 mg/ml) or a control antibody of
irrelevant specificity (anti-HA, 12CA5; Roche, 0.3 mg/ml). Data were
normalized to luciferase activity in cells incubated with untreated virus.
Each data point represents the mean6SD of 3 independent exper-
iments. (B) Luciferase entry assays were performed using VSVP, EVP, or
FrVP on HEK293-mCAT-1 cells in the presence of either 20 mM
ammonium chloride (open bars) or 50 nM bafilomycin A1 (solid bars).
Effect of ammonium chloride was also tested on ZEBO-VLP. Data were
normalized to luciferase activity for untreated cells. Each data point
represents the mean6SD of 3 independent experiments. (C) Kinetics of
entry was measured for EVP (open squares), VSVP (closed squares), and
ZEBO-VLP (open circles). Each was incubated with HEK293-mCAT1 cells
at room temperature. After 10 min, cells were washed to remove
unbound virus and incubated at 37uC. At indicated time intervals,
aliquots of cells were withdrawn, and luciferase signals were measured.
For each virus, luciferase activity at different time points was normalized
to the maximum luciferase activity for that virus. Each data point
represents the mean6SD of 2 independent experiments.
doi:10.1371/journal.ppat.1000141.g003
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be an important downstream effector. PI3K-Akt is one prominent
activation pathway for Rac1 in many cell types [13–16].
Treatment with PI3K, Akt or Rac1 inhibitors all led to similar
intracellular accumulation of ZEBOV particles (Figure 6), signi-
fying a common block in one of the stages of ZEBOV uptake into
cells. A similar clustering of internalized EphA2 receptor in
endocytic vesicles was also observed after treatment with inhibitors
of PI3K, Akt or Rac1 [43]. The likely role of Rac1, was through its
regulation of actin polymerization, which plays a pivotal role in a
variety of actin-dependent cellular processes such as membrane
ruffling, receptor-mediated endocytosis and vesicular trafficking
[12]. Indirect evidence suggesting that control of actin polymer-
ization may be important for ZEBOV infection came from
observations that: (i) internalized ZEBOV particles were in close
proximity to actin bundles or filaments; (ii) inhibitors of PI3K, Akt
and Rac1 all caused similar changes in F-actin characterized by
loss of membrane ruffling and focal adhesions (data not shown);
and (iii) agents that perturb actin dynamics significantly inhibit
EVP entry [26].
Early activation of the PI3K-Akt pathway by ZEBOV may also
have implications in pathogenesis of Ebola virus hemorrhagic fever.
A profound inflammatory response is a key feature of the disease.
Macrophages are among the primary targets of ZEBOV infection
and respond by producing a number of proinflammatory cytokines
and chemokines including TNF-a, IL-6 and IL-8 [44]. This appears
to occur in the absence of virus replication as Ebola virus-like
particles (VLPs) stimulate the same set of cytokines and is dependent
on the presence of the Ebola virus envelope glycoproteins [45]. It
follows that Ebola virus envelope proteins may play a vital role in the
proinflammatory response induced during the infection. There is
also evidence that the PI3K-Akt pathway contributes significantly
toward regulation of each of these cytokines [46–49]. ZEBOV-
induced activation of the PI3K-Akt pathway could then directly
Figure 4. PI3K-Akt-1 pathway plays a critical role in Ebola virus entry. (A) HEK293-mCAT-1 cells were pre-treated with the indicated
concentrations of LY294002 for 1 h followed by incubation with ZEBO-VLP (open squares), VSV-VLP (closed squares), EVP (open circle), or VSVP
(closed circle) for 3 h in the continued presence of the drug. Entry signals were then measured. Data were normalized to luciferase activity in DMSO
(vehicle)-treated cells. (B) HEK293-mCAT-1 cells were pre-treated with the indicated concentrations of Akt inhibitor for 1 h followed by incubation
with ZEBO-VLP (open squares), VSV-VLP (closed squares), EVP (open circle), or VSVP (closed circle) for 3 h in the continued presence of the drug. Entry
signals were then measured. Data were normalized to luciferase activity in DMSO (vehicle)-treated cells. (C) HEK293-mCAT-1 cells were transfected
with either pcDNA3 or pcDNA3 encoding a dominant-negative form of the PI3K p85-a regulatory subunit (Dp85a). Entry assays were performed 36 h
after transfection using ZEBO-VLP (open bars) or VSV-VLP (solid bars). Data were normalized to luciferase activity in untransfected cells. Each data
point represents the mean6SD of 3 experiments. (D) Wild-type (WT), pik3R1
2/2 (p85a, p55a, and p50a-deficient), or pik3R2
2/2 (p85b -deficient)
mouse embryonic fibroblast (MEF) cells were incubated with EVP (open bars) or FrVP (solid bars). After 3 h, cells were washed, and luciferase activity
was measured. Each data point represents the mean6SD of 3 independent experiments. (E) HEK293-mCAT-1 cells were pre-treated with LY294002
(50 mM) or Akt-1 inhibitor (1.0 mM) for 1 h at 37uC, followed by incubation with ZEBO-VLPs for 10 min at room temperature. Cells were then washed
to remove unbound virus and resuspended in luciferase assay buffer containing triton X-100 detergent; luciferase activity was then measured. Data
were normalized to luciferase activity in vehicle-treated samples. Each data point represents the mean6SD of 2 experiments.
doi:10.1371/journal.ppat.1000141.g004
Ebola Virus Entry Mechanism
PLoS Pathogens | www.plospathogens.org 6 August 2008 | Volume 4 | Issue 8 | e1000141contribute to the proinflammatory response. Another hallmark of
ZEBOV infection is hemorrhage due to increased vascular
permeability. Vascular dysregulation has been attributed to both
direct invasion and replication of ZEBOV in vascular endothelial
cells, and to action of ZEBOV-induced proinflammatory cytokines,
especially TNF-a, on vascular endothelial cells [50]. Also, PI3K-Akt
pathwayactivationdoesleadtoincreasedvascularpermeability[51].
Thus, whether the mechanism of vascular dysregulation is through
virus replication or action of cytokines, ZEBOV-induced PI3K
activation has ability to affect both mechanisms, and thereby can
potentially influence and partly explain a mechanism of ZEBOV
pathogenesis.
The PI3K pathway is vital for regulation of diverse cellular
activities, including growth, survival, differentiation and motility.
There is mounting evidence that aberrant regulation of the PI3K
pathway is central to development and/or progression of many
forms of cancer [40]. As a result, considerable effort is currently
being focused on developing therapeutic strategies targeting
various components of this pathway, including targeting specific
isoforms and subunits of the PI3K holoenzyme [52]. Earlier this
year a PI3K inhibitor entered phase 1 clinical trials indicating that
such drugs are becoming available [53]. The finding that the PI3K
pathway is also essential for entry of ZEBOV is therefore highly
relevant for design of new therapeutic strategies and provides new
potential opportunities where PI3K inhibitors developed for
cancer treatments may become equally useful for treatment
ZEBOV infection.
Materials and Methods
Cells and culture
HEK293 and HEK293FT human fibroblast-derived cells were
purchased from ATCC and Invitrogen, respectively. HEK293-
mCAT-1 are a clonal derivative of HEK293 cells that express the
mCAT-1 protein which serves as a receptor for ecotropic murine
leukemia viruses (MLV), such as the Friend 57 strain of MLV
(Entrez nucleotide #X02794). These cells have similar morphol-
ogy and growth properties compared to the parental HEK293
cells. Inhibition of ZEBOV entry by PI3K inhibitors was also
confirmed in HEK293 cells with similar outcomes (data not
shown). Vero-E6 cells were also purchased from ATCC. HEK293,
FT and Vero-E6 cells were maintained in Dulbecco’s modified
Eagle’s (DMEM) medium supplemented with 10% fetal bovine
serum (Gemini Bioproducts, GA), 1% non-essential amino acids
(Sigma, MO) and 1% penicillin-streptomycin solution (Sigma,
MO). HEK293FT cells were used for pseudotype production and
were maintained in the presence of geneticin at 0.5 mg/ml. Mouse
embryonic fibroblasts (MEFs) were isolated from embryos that
were heterozygous or homozygous for knockout of the PI3K-
family related genes pik3R1 and pik3R2. Immortalized cells from
these embryos were provided by Dr. Lew Cantley (Harvard
Medical School, MA) and were cultivated in the above medium.
Antibodies
ZEBOV-specific KZ52 monoclonal antibody was a gift from
Dr. Dennis Burton (Scripps Research Institute, LaJolla, CA). Anti-
Akt-1 and anti-phospho-Akt-1 antibodies were purchased from
Cell Signaling Technologies (Danvers, MA). Anti-HA (12CA5)
was used as a non-specific control monoclonal antibody (Roche,
IN).
Plasmid constructs
All plasmids were prepared using Qiagen kits or by CsCl
gradient centrifugation following standard procedures. The
plasmids encoding HIV-1 gag and polymerase (pLP1), HIV-1
Rev (pLP2) and VSV-G envelope glycoprotein (pLP-VSVG) were
purchased from Invitrogen. Construction of the plasmids encoding
packageable enhanced green fluorescent protein (pLenti-EGFP)
and Nef-luciferase fusion protein (pCDNA3-nef-luc) has been
described previously [24]. Plasmid encoding ZEBOV matrix
protein (VP40) (Entrez gene#NC002549) and envelope glycopro-
teins were kindly provided by Dr. Christopher Basler (Mount Sinai
School of Medicine) and Dr. Paul Bates (University of Pennsylva-
nia), respectively. The plasmid encoding envelope protein of the
Friend 57 strain of MLV (pFr-Env) has been described previously
[54].
Figure 5. Rac1 plays a role in ZEBOV entry and serves as a
downstream effector of Akt-1 signaling. (A) HEK293-mCAT-1 cells
were treated with indicated concentrations of Rac1 inhibitor, and entry
assays were performed using ZEBO-VLP (open squares), VSV-VLP (closed
squares), EVP (open circles), or VSVP (closed circles). Data points
represent the average6SD of 2 experiments. (B) HEK293-mCAT-1 cells
were transfected with either pcDNA3 vector lacking insert, or pcDNA3
encoding dominant-negative Rac1 (Rac1-T17N) or pcDNA3 encoding
constitutively active Rac1 (Rac1-G12V). Entry assays were performed
36 h later using ZEBO-VLPs (open bars) or VSV-VLP (solid bars) in the
absence or presence of Akt inhibitor. Results are expressed as the
percent of luciferase activity in untransfected cells. Each data point
represents the mean6SD of 2 experiments. (C) Cells transfected with
plasmids encoding HA-tagged Rac1-T17N (left panel), Rac1-G12V
(middle panel), or empty vector (right panel) were stained using anti-
HA mouse monoclonal antibody and Alexafluor594-conjugated anti-
mouse IgG.
doi:10.1371/journal.ppat.1000141.g005
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HEK293FT cells were grown to approximately 80% conflu-
ence in 10-cm diameter dishes. The cells were simultaneously
transfected with plasmids: (i) pLP1 (3 mg), pLP2 (2 mg), pLenti-
EGFP (2 mg), pcDNA3-Nef-luc (1.5 mg) and one of the following
envelope protein constructs pLP-VSVG, 2 mg; pFr-Env, 5 mg;
pEbola-GP, 0.5 mg to yield pseudotyped viruses with VSV,
Friend 57 MLV or ZEBOV envelope glycoproteins respectively.
Transfection was by calcium-phosphate precipitation [55]. After
overnight incubation, culture medium was replenished and the
plate was incubated for a further 36 h. At this time, the cell
culture supernatant was collected and filtered through a 0.45-mm
pore size cellulose-acetate filter to remove cell debris. Virus in
the filtrate was pelleted by centrifugation through a 20% (w/v)
sucrose cushion in PBS. Centrifugation was for 3.5 h at
25,000 rpm in SW28 rotor at 4uC. The virus pellet was
resuspended in 0.01 volume of DMEM, aliquoted and stored
at 280uC until used.
Figure 6. Inhibitors of PI3K, Akt, and Rac1 cause intracellular clustering of ZEBOV particles. (A) HEK293-mCAT-1 cells were grown on
chambered coverglass and treated with DMSO (control) or the indicated drugs for 1 h, followed by incubation with fluorescently labeled ZEBOV (red)
for 3 h. Cells were fixed, permeabilized, and incubated with Alexafluor488-labeled phalloidin to visualize F-actin and DAPI to stain nuclei (blue).
Subsequently, slides were washed and photographed by fluorescence microscopy using a 1006oil immersion objective. Scale bars are shown at
lower right and apply to all images in the panel. (B) The observations made using HEK293-mCAT-1 cells were confirmed in Vero-E6 cells by confocal
microscopy. (Top panel) Serial optical sections of cells treated for 1 h with DMSO (left) or the PI3K inhibitor LY294002 (right) and then incubated with
fluorescently labeled ZEBOV (red) for 2 h. Cells were fixed and stained with phalloidin to label F-actin (green) and DAPI to label cell nuclei (blue). The
level of the section is indicated, with 0 on the basolateral cell surface and 6 mm close to the apical surface of the cell. (C) Volume projection of all
optical z-sections (computed using ImageJ software) of representative cells incubated in the presence of DMSO or LY294002. In DMSO-treated cells,
examples of actin bundles adjacent to virus particles are indicated by arrowheads. Only the red and green fluorescence channels are shown, and the
nuclei of chosen cells are indicated with dashed lines.
doi:10.1371/journal.ppat.1000141.g006
Ebola Virus Entry Mechanism
PLoS Pathogens | www.plospathogens.org 8 August 2008 | Volume 4 | Issue 8 | e1000141Production of virus-like particles containing Nef-
luciferase fusion protein
ZEBOV-VLPs were produced by co-transecting HEK293 cells
with plasmids encoding ZEBOV matrix protein (VP-40), Zaire Ebola
virus (ZEBOV) envelope glycoproteins, and Nef-luciferase fusion
protein using the calciumphosphate method. For VSV-VLP, plasmid
encoding Ebola virus glycoproteins was replaced with one encoding
VSV-G. Cellculture supernatant wascollected 48 h after transfection
and cell debris was cleared by centrifugation (1,200 rpm for 10 min
at 4uC). Subsequently, VLPs were purified by centrifugation
(25,000 rpm in SW28 rotor for 3.5 h at 4uC) through a 20% (w/v)
sucrose cushion in PBS. The VLP pellet was resuspended in 0.01
volume of DMEM, aliquoted and stored at 4uC. Assays were
performed within 2–3 days after purification of VLPs.
Cultivation of ZEBOV and determination of virus titer
Zaire Ebola virus (Mayinga strain), was cultivated on Vero-E6
cells by infection at an MOI of 0.1. Culture supernatants were
collected after 10 d and clarified by centrifugation at 20006g for
15 min. Virus titer was determined by serial dilution in Vero-E6
cells. Cells were incubated with virus for 1 h and then overlaid
with 0.8% (w/v) tragacanth gum in culture medium. 10 d post-
infection cells were fixed with formalin, and stained with crystal
violet so that plaques could be counted. All experiments with
ZEBOV were performed under biosafety level 4 conditions in the
Robert E. Shope BSL-4 Laboratory, UTMB.
Determination of pseudotype virus titer
HEK293-mCAT-1 cells were grown in a 96-well plate to
approximately 50% confluence. Serial 5-fold dilutions of virus
stocks were prepared in DMEM and 50 ml of each dilution was
added to cells. After overnight incubation, the medium was
replenished and the incubation continued until GFP expressing
cells were apparent (2 d post-infection). The total number of GFP-
positive colonies was counted in each well using an inverted
epifluorescence microscope and the titer of stock virus was
calculated.
Virus entry assay
Cells were removed from plates by trypsin treatment, pelleted
by centrifugation and then resuspended in fresh medium.
HEK293 cells (10
6) were mixed with Nef-luciferase containing
pseudotyped virus or VLPs in a volume of 0.2 ml and incubated at
37uC on a rotating platform for indicated time intervals. Exposure
of cells to low temperatures (4uC) was avoided as this is known to
temporarily disrupt endocytosis and receptor trafficking upon
return to 37uC. To remove excess virus particles, cells were
pelleted by centrifugation at 2006g for 5 min, supernatant
containing unbound virus was discarded, and the cell pellet was
washed 3 times with DMEM. The final cell pellet was resuspended
in 0.1 ml of luciferase assay buffer lacking detergent (Promega,
WI) and luciferase activity measured using a Turner Design TD
20/20 luminometer and expressed as counts/sec.
For antibody inhibition assays, the luciferase-containing pseu-
dotyped virus or VLPs were incubated with antibody for 1 h prior
to incubation with target cells, which was performed in the
continued presence of antibody.
To study drug activity on virus entry, cells were pre-treated for
1 h, followed by incubation with pseudotyped virus or VLPs in the
continued presence of the drug. Virus entry was then measured as
described above.
For dominant-negative or constitutively-active mutants, control
plasmid (pcDNA3) or plasmid encoding the modified cDNA was
transfected into HEK293-mCAT-1 cells by calcium phosphate
precipitation as described above. Cells were used for entry assays
36 h after transfection.
Analysis of Akt-1 phosphorylation
HEK293 cells were grown to confluence and then serum-starved
for 12–14 h. Radiation-inactivated wild type ZEBOV (Entrez
Genome#15507) or VSV (Entrez Genome#10405) (sucrose
purified and resuspended in serum-free medium) was then added
at a calculated MOI of 5. For positive control, cells were treated with
10% fetal bovine serum in medium, while the negative control
samples received serum-free medium. All samples were incubated at
37uC for times indicated. After the incubation, cell lysates were
applied to 10% polyacrylamide gels and resolved proteins
transferred to a nitrocellulose membrane by electroblotting. After
blocking the membrane in 5% milk powder in TBST, blots were
incubated overnight with anti-phospho-Akt-1 antibody at 4uC,
washed and incubatedwith HRP-conjugated secondaryantibodyfor
1 h. The membrane was then washed and developed using ECL
chemiluminescence substrate (GE life sciences, Piscataway, NJ) and
imaged. Subsequently, the same membrane was stripped and re-
probed for total Akt-1 using an anti-Akt-1 antibody. Band
densitometry was performed using ImageJ analysis software [56].
Labeling of ZEBOV with fluorescent dye
ZEBOV was grown on Vero-E6 cells to a titer of 10
6 pfu/ml.
Virus-containing culture supernatant was clarified by pelleting cell
debris at 20006g for 15 min. The virus remaining in the
supernatant was then pelleted through 20% sucrose in 10 mM
HEPES, pH 7.4 by centrifugation at 100,0006g for 3 h. The virus
pellet was resuspended in 140 mM NaCl in 10 mM HEPES,
pH 7.4 and inactivated by gamma-radiation (5 Mrad). Protein
content of the virus pellet was determined using a BCA protein
assay kit (Pierce, Rockford, IL). An equal volume of 0.1 M sodium
phosphate, pH 8.0 was added and protein concentration adjusted
to 2 mg/ml by further addition of this buffer. Of this, 0.1 mg of
total protein was labeled with 0.05 mg of Alexa Fluor594
carboxylic acid, succinimidyl ester (Invitrogen). The reaction was
allowed to proceed for 2 h at room temperature at which time it
was quenched by addition of 0.1 volume of 0.1 M glycine. The
samples were then dialyzed overnight against PBS at 4uC and then
again overnight against DMEM. The virus suspension was then
aliquoted and stored at 280uC.
Microscopy
HEK293-mCAT-1 or Vero-E6 cells were cultivated overnight
on chambered coverglass (Nunc, Rochester, NY) at a density of
50%. The following day, cells were incubated with fluorescently-
labeled ZEBOV for 3 h. For analysis of drug action, cells were
pretreated for 1 h prior to virus addition as described above. Cells
were then washed three times in DMEM and fixed in 3.5% fresh
paraformaldehyde in PBS. After one wash in PBS residual
paraformaldehyde was neutralized by addition of 0.1 M glycine
buffer, pH 7.4 and cells were permeabilized using 0.1% Triton X-
100 for 1 min at room temperature. Cells were stained for F-actin
using Alexa488-conjugated phalloidin (Invitrogen) for 15 min at
room temperature. Cells were imaged using a Leica DMIRB
inverted microscope with a 1006 oil immersion lens or a Zeiss
LSM 510 confocal microscope in the UTMB optical imaging core.
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